Evidence map›Paper›PMID 42681212›Full record

ArticleInternational journal of clinical oncology2026

Histological heterogeneity of SLFN11 expression and its association with response to carboplatin plus paclitaxel therapy in salivary gland cancer.

Satoshi Kano, Seijiro Hamada, Jun Taguchi, Nayuta Tsushima, Hiroshi Idogawa, Hayato Imanari, Masaki Kakumu, Mai Sakai, Yasushi Shimizu, Akihiro Homma

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Satoshi KanoDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 060-8638, Japan. skano@med.hokudai.ac.jp.ORCID http://orcid.org/0000-0003-4750-5332
Seijiro HamadaDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 060-8638, Japan.
Jun TaguchiDepartment of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Nayuta TsushimaDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 060-8638, Japan.
Hiroshi IdogawaDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 060-8638, Japan.
Hayato ImanariDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 060-8638, Japan.
Masaki KakumuDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 060-8638, Japan.
Mai SakaiDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 060-8638, Japan.
Yasushi ShimizuDepartment of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Akihiro HommaDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, 060-8638, Japan.

Funding

Japan Society for the Promotion of Science 24K12689
6 · The paper itself

Abstract

backgroundSchlafen family member 11 (SLFN11) has emerged as a potential biomarker of sensitivity to DNA-damaging agents, including platinum compounds. However, its expression profile and clinical significance in salivary gland cancer (SGC) remain poorly understood. This study investigated the histological distribution of SLFN11 expression and its association with response to carboplatin plus paclitaxel (CBDCA+PTX) therapy in SGC.

methodsSLFN11 expression was assessed by immunohistochemistry using an H-score-based method. Associations between SLFN11 expression and histological grade or subtype were evaluated. In addition, treatment outcomes were analyzed in patients who received CBDCA+PTX as first-line systemic therapy for recurrent or metastatic disease. Objective response rate (ORR) was assessed according to RECIST version 1.1, and progression-free survival (PFS) was estimated using the Kaplan-Meier method.

resultsSLFN11 expression demonstrated significant heterogeneity among histological subtypes and was enriched in high-grade tumors, particularly salivary duct carcinoma and squamous cell carcinoma. Seventeen patients treated with CBDCA+PTX were included in the efficacy analysis. In the overall cohort, ORR was numerically higher in the SLFN11-high group than in the SLFN11-low group (60% vs. 29%; odds ratio, 3.75). A similar tendency was observed in the non-adenoid cystic carcinoma (non-AdCC) subgroup (75% vs. 50%; odds ratio, 3.00). In contrast, PFS did not differ by SLFN11 expression status.

conclusionsSLFN11 expression varies substantially across histological subtypes of SGC and is enriched in high-grade tumors. SLFN11-high tumors showed higher response rates to CBDCA+PTX therapy, suggesting that SLFN11 may be associated with initial tumor response to platinum-containing chemotherapy, although this finding is exploratory and hypothesis-generating.

Indexed as

Adenoid cystic carcinomaCarboplatinSalivary duct carcinomaSalivary gland cancerSLFN11

Identifiers

PMID42681212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.